10 TH ANNIVERSARY Summary report on CQDM economic impact - PowerPoint PPT Presentation

10 TH ANNIVERSARY Summary report on CQDM economic impact 2008-2018 Presented by : Diane Gosselin, CEO Novembre 2018

Founded in in 2008 by Vis isionaries Dawn Graham Max Fehlmann Alain Beaudet Paul Lévesque Bernard Prigent Philippe Walker 3

A Uniq ique Coll llaborativ ive Model in in 2008 MISSION : ACCELERATE DRUG DISCOVERY AND DEVELOPMENT Pharma driven ◼ A collaborative ground between the private ◼ and academic sectors An emerging model in 2008 ◼ A lot of skepticism towards the CQDM model ◼ 4

A Sig ignific icant Fin inancia ial Leverage to Fill ill the Gap PHARMA GOVERNMENTS CO-FUNDING PARTNERS 5

A Sig ignific icant Fin inancia ial Leverage to Fill ill the Gap GOVERNMENTS CO-FUNDING PHARMA PARTNERS 6

A Sig ignific icant Fin inancia ial Leverage to Fill ill the Gap GOVERNMENTS CO-FUNDING PARTNERS 7

A Sig ignific icant Fin inancia ial Leverage to Fill ill the Gap HIGH-RISK, HIGH-REWARD PROJECTS ◼ Stimulate innovation by supporting early stage translational research ◼ Bridge academic research to the private sector ◼ Generate benefits for the academic and private sectors ◼ Address critical needs of the bio-pharmaceutical research 8

A Survey to Measure the Im Impact of CQDM AREAS COVERED Enabling technologies, products and services generated ◼ The survey reflects the point Impact on the creation and growth of SMEs OVERALL OBJECTIVE ◼ of view of the Additional funding for academic institutions and SMEs ◼ Scale the impact of funded Follow-on partnerships with the pharma industry INVESTIGATORS ◼ projects on the ecosystem Jobs and trainings ◼ Outreach ◼ SOURCE OF QUANTITATIVE AND QUALITATIVE INFORMATION Annual and quarterly reports from the projects ◼ The survey reflects In depth survey on 64 projects ◼ the point of view of the Over 100 people interviewed (investigators and entrepreneurs involved in the ◼ projects) INVESTIGATORS Under the leadership of Gilles Duruflé, Economist 9

Searchin ing for Scie ientific Excellence, , In Innovation and Im Impact 10 $68M 64 1200 FUNDING PROGRAMS FUNDING PROJECTS RESEARCHERS 49 calls for proposals $44M CQDM 25 Qc only 165 academic labs 825 proposals reviewed $24M Co-funding 11 Qc & International 31 SMEs partners 16 Qc & others provinces 12 outside Qc 10

A Number of Partnership ips Fostered STRATEGIC LEVERAGE: 165 31 ACADEMIC SMEs ◼ ACCELERATE INNOVATION LABS ◼ INCREASE OUTREACH ◼ STIMULATE COMPANY GROWTH 10 ◼ ENHANCE COMPETITIVENESS LEADING PHARMA 11

64 projects funded 500 products, services 88% success rate 47 completed and research tools deliverables achieved 5 terminated generated from CQDM during funding projects 12 active 12

Dia iagnostics and Research Tools Develo loped 30 DIAGNOSTICS 11 17 2 Discovery Clinical validation Market 309 14 INSTRUMENTS RESARCH TOOLS 5 3 6 Discovery Prototype Market 100 68 55 Assays Animal models Cell lines 265 20 13 9 OTHER TOOLS Methods & Processes Softwares Databases 13

Several Therapeutic ics Generated from Pla latforms Developed 131 THERAPEUTICS IN DEVELOPMENT Validated 56 105 21 2 2 1 PLATFORMS Used in Discovery Preclinical Phase I Phase II Phase III Drug discovery research/ Drug delivery Commercialized Drug screening 14

The Medic icago Example Seasonal Influenza : Phase III VLPExpress New programs initiated Rotavirus: Phase I discovery platform Norovirus: preclinical CQDM funding Rotavirus 3 undisclosed Seasonal Norovirus influenza 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 Pandemic Ebola influenza Publicly owned Privately owned Phase II Market cap: $80M Raised over $300M 65 employees in investment Manufacturing optimization Pandemic Influenza vaccine - Phase I 350 employees $245M Factory Investment (Quebec) 15

More than $194M in in Follow-on In Investments for r the the de development of of CQDM-funded technologie ies SOURCE OF FUNDS PRIVATE COMPANIES Pharma SMEs INVESTORS PRIVATE FOUNDATIONS PUBLIC AGENCIES CONSORTIA $10M $20M $30M $40M $50M 16

Jo Jobs and Trainings Supported CQDM-FUNDED PROJECTS FOLLOW-ON 520 FTEs x year supported 1200 (including 191 students trained) FTEs x year highly skilled resources A network of 1200 researchers (estimated) ( 136 mentors from global pharma) 17

A Colla llaborative Approach that Generates Benefit its for SMEs 165 31 ◼ 6 Start-ups ACADEMIC SMEs ◼ Growth of 40 existing companies LABS ◼ 1 foreign company established in Quebec 10 LEADING PHARMA 18

Benefits Generated for SMEs ACCES TO INNOVATION DEVELOPMENT OF NEW PRODUCTS INCREASED RESEARCH CAPACITY UNIQUE FUNDING FOR R&D PARTNERSHIPS WITH PHARMA FUND RAISING 0% 20% 40% 60% 80% 100% % positive responses among entrepreneurs interviewed 19

Benefits Generated from the Phama SUPPORT OF CQDM FUNDED PROJECTS ◼ $14M initial funding ◼ 136 mentors from global Pharma 165 31 ◼ Market pull approach ACADEMIC SMEs LABS PARTNERS FOR THE FUTURE ◼ 71 follow-on interactions and 10 partnerships with 26 different Pharma LEADING ◼ $41M follow-on investments PHARMA 20

A Very ry Im Impressiv ive Fin inancial Leverage 300 13.2x 250 200 $1 of Qc government $1 of Qc government Follow-on $M invested investments funding generates funding generates 150 $4.2 for R&D $13.2 total funding 4.2 .2x 100 Funding of CQDM projects 50 (64) QC GOV. 0 21

Conclusion • A CATALYST TO THE CULTURE OF COLLABORATIVE INNOVATION IMPACT • TRANSFORMATIVE EFFECT GENERATED FROM FUNDING BEYOND • A MODEL THAT DELIVERS HIGH VALUE PRODUCTS AND SERVICES EXPECTATIONS • FILLS THE GAP TO FOSTER INNOVATION 22

Breaking up the Silo ilos to Conquer the Future 23

A D Dedic icated Team Diane Gosselin Michael Bridges Steven Xanthoudakis Mario Chevrette Marc Thibault Véronique Dugas Mathieu Perrée Rebeca Baca-Diaz Jennifer Saleeb Olivier Carter Naëla Janmamode 24

A Rig igorous Scie ientific An Exp xperie ienced Board Advis isory Board Chairman Chairman Richard Fajzel , CEO, Exactis Innovation Daniel Hétu , Managing Director, Lumira Capital Members Members Jennifer Chan , VP, Policy and Communications, Merck Canada Karen Akinsanya , Chief Biomedical Scientist, Schrödinger Diane Gosselin , President and CEO, CQDM André Darveau , Vice Rector, Administration, Raphael Hofstein , President and CEO, MaRS Innovation Université Laval Ken Pastor, General Partner, CTI Capital Diane Gosselin , President and CEO, CQDM Louise Proulx, Chief Development Officer, Therillia Reid Jason Leonard, Senior VP, Corporate Jorge Puente , Managing Partner, Pleasanton Pharma Ventures Development, Potenza Therapeutics Rémi Quirion , Quebec Chief Scientist Mark Lim , Assistant Director of Global Public Uwe Schoenbeck, Senior VP & CSO, External R&D Innovation, Health Programs, American Society for Pfizer worldwide R&D Microbiology Ali Tehrani , Co-founder, President and CEO, Zymeworks Patrick J. Wier , Senior VP, In Vitro/In Vivo Translation Platform, GSK 25

An Ext xtended Canadian and In International Partner Network 26